Iron Overload (High Iron): Heart Problems

Table of Contents

1. What It Feels Like
2. The Mechanism: Why Excess Iron Poisons the Heart
3. Heart Symptoms Are Not Specific to Iron
4. When Heart Symptoms Point Toward Iron
5. Why Iron Builds Up in the First Place
6. Getting Checked: Blood Tests and Cardiac Magnetic Resonance Imaging
7. How It Is Treated — and Why It Can Reverse
8. Heart Checks and Emergency Warning Signs
9. Key Research Papers
10. Connections
11. Featured Videos

What It Feels Like

The hard truth about iron-overload heart disease is that it is silent for a long time. Iron accumulates in the heart gradually, often over a decade or more, and the muscle can hold a surprising amount before anything feels wrong. By the time symptoms appear, a meaningful amount of iron has usually already deposited — which is exactly why doctors who care for high-iron patients screen the heart before symptoms start rather than waiting for them.

When the heart finally does complain, it tends to do so in one of two overlapping ways: as a problem of pumping (cardiomyopathy and heart failure) or as a problem of rhythm (arrhythmia). The common experiences include:

• Breathlessness on exertion. The earliest and most common complaint. Climbing stairs, walking uphill, or carrying groceries leaves you winded sooner than it used to, because a stiff or weakened heart cannot raise its output to meet the demand.
• Reduced exercise tolerance and fatigue. A general drop in stamina — you tire faster and recover more slowly. (High iron causes fatigue and joint pain through other routes too, so tiredness alone is a weak clue.)
• Palpitations. A fluttering, pounding, skipping, or racing heartbeat. Iron-laden hearts are prone to arrhythmias — extra beats, atrial fibrillation, and at the dangerous end, ventricular rhythms. Some people feel an irregular pulse; others feel a sudden gallop for no reason.
• Swelling and fluid retention. As the failing heart backs up, fluid collects in the ankles, legs, and abdomen, and lying flat at night brings on breathlessness (people prop themselves up on extra pillows).
• Lightheadedness, near-fainting, or fainting. A fast or chaotic rhythm, or a heart that cannot keep output up, can drop blood pressure enough to make you dizzy or briefly black out — a warning sign that hospitals treat as urgent.

None of these sensations announces “iron” they are the universal language of an ailing heart. What distinguishes iron-overload cardiomyopathy is not how it feels but the context in which it appears: a person who has received many blood transfusions, who has hereditary hemochromatosis, or who has been taking high-dose iron for years. The next sections explain the mechanism, then return to those telling clues.

Back to Table of Contents

The Mechanism: Why Excess Iron Poisons the Heart

To understand the damage, it helps to know how careful the body normally is with iron. Iron is indispensable — it carries oxygen in hemoglobin and powers the energy factories of every cell — but a loose iron atom is also chemically vicious. So the body keeps almost all of its iron bound: locked onto the transport protein transferrin in the blood, and packed into the storage protein ferritin inside cells. Tightly held iron is safe iron. (The body's master switch for all of this, the hormone hepcidin, is described on the Iron overview.)

Iron overload breaks that discipline. When there is far more iron than transferrin can hold, the surplus circulates as non-transferrin-bound iron (NTBI) — free, reactive iron with nothing to restrain it. This is the dangerous form, and the heart is unusually exposed to it.

How iron gets into heart cells — the calcium-channel surprise. Here is the twist that makes the heart so vulnerable. Heart muscle cells (cardiomyocytes) do not have a big front door for ordinary, transferrin-bound iron. But they are studded with L-type calcium channels — the same gates that let calcium rush in to trigger each heartbeat. It turns out that loose NTBI can sneak through these calcium channels into the cell. Landmark experiments showed that L-type calcium channels are a major pathway for iron entry into cardiomyocytes, and that blocking those channels reduces how much iron the heart takes up. In effect, the heart's own contraction machinery doubles as an unguarded side entrance for toxic iron.

What happened when this was tested in people. Those calcium-channel experiments were done in animals and in heart cells. In people, a 2023 Cochrane review pooled six randomised trials (253 people with transfusion-dependent beta thalassaemia) in which amlodipine, a calcium-channel-blocking blood-pressure drug, was added to standard iron chelation. After 12 months, adding amlodipine may slightly lower the measured iron concentration in the heart muscle (by 0.27 mg/g), but it may make little or no difference to cardiac T2* or to the heart's pumping strength (left ventricular ejection fraction). Ankle and leg swelling (oedema) was more common on amlodipine, no serious side effects were reported, and the reviewers rated the evidence as low certainty for most outcomes.

What the iron does once inside. Free iron is a catalyst for damage. Through a chemical reaction (the Fenton reaction) it generates a storm of reactive oxygen species — unstable molecules that, like rust eating through metal, corrode the cell from within. They damage the cell membranes, injure the mitochondria (the energy plants the heart depends on to beat tirelessly), and disturb the handling of calcium that times each contraction. Over years, individual heart cells weaken and die, and scar tissue replaces them. The muscle first becomes stiff (a restrictive pattern, where the heart cannot relax and fill properly), and later becomes dilated and weak (where the stretched chambers cannot squeeze with force) — full-blown heart failure.

The very same iron also disrupts the heart's electrical wiring. Oxidative injury and disordered calcium handling make heart cells fire erratically, and iron deposits in the conduction system can slow or short-circuit the orderly electrical wave — producing the palpitations, atrial fibrillation, and dangerous ventricular rhythms that accompany iron-overload heart disease.

An analogy. Think of a city water system. Properly contained in pipes (transferrin and ferritin), water is purely useful. But let it spill and pool, and it seeps everywhere — rusting the wiring, shorting the breakers, and rotting the structural beams. Iron-overload cardiomyopathy is that slow flood: the heart's beams (the muscle) sag and the wiring (the rhythm) shorts out. Mop up the flood early — remove the excess iron — and much of the structure dries out and recovers. Let it pool for years and the damage becomes permanent.

Back to Table of Contents

Heart Symptoms Are Not Specific to Iron

It is essential to be candid here: breathlessness, palpitations, swelling, and fainting are among the least specific symptoms in all of medicine. Iron overload is an uncommon cause of them. The overwhelming majority of people with these complaints have a heart problem that has nothing to do with iron. Common causes include:

• Coronary artery disease and prior heart attacks — the leading cause of heart failure in most of the world.
• High blood pressure, which over years thickens and stiffens the heart.
• Valve disease — a leaky or narrowed heart valve.
• Atrial fibrillation and other primary rhythm disorders arising from the conduction system itself (see arrhythmia and atrial fibrillation).
• Thyroid disease, anemia, lung disease, and deconditioning, all of which cause breathlessness and a fast or pounding heartbeat.
• Other cardiomyopathies — viral, genetic, alcohol-related, or from chemotherapy — that look identical to the iron kind on a first scan.

Because the symptoms overlap so completely, the diagnosis of iron-overload cardiomyopathy is almost never made from symptoms alone. It is made when a clinician notices the setting — a reason to suspect high iron — and then proves it with blood tests and a cardiac magnetic resonance imaging (MRI). A person worried about palpitations who has none of the iron-overload risk factors below is far more likely to have one of these ordinary causes, and those are the causes a heart workup usually looks at first. The point of this page is not to make every palpitation a fear of iron; it is to make sure iron is not missed in the specific people who carry too much of it.

Back to Table of Contents

When Heart Symptoms Point Toward Iron

Iron-overload cardiomyopathy becomes a real consideration — and sometimes the leading one — when heart symptoms appear in a person who has a recognized reason to be iron-loaded. The strongest clues are:

• Many blood transfusions. This is the single biggest red flag worldwide. People with thalassemia major, sickle cell disease, myelodysplastic syndromes, or other conditions requiring regular transfusions accumulate iron with every unit of blood, and the heart is the organ that determines their survival. New breathlessness or arrhythmia in a chronically transfused patient is treated as cardiac iron until proven otherwise.
• Hereditary hemochromatosis. An inherited tendency to absorb too much iron from food. Cardiac involvement is less common than in transfusional overload but still occurs, especially when the diagnosis is made late. See hemochromatosis.
• The company iron keeps in other organs. Iron rarely picks on the heart alone. Clues in other systems strengthen the case: an enlarged or scarred liver, new bronze-gray skin and diabetes (the classic “bronze diabetes”), joint pain, or loss of sex drive from hormone gland involvement. A heart problem alongside any of these is a recognised reason for an iron check.
• Years of high-dose iron supplements or injections taken without a proven deficiency, particularly in someone who also has a genetic predisposition.
• A markedly high ferritin and transferrin saturation already on file. If routine blood work has shown high iron markers, a new heart symptom takes on a different meaning.

When several of these align — say, palpitations and breathlessness in a transfused patient with a high ferritin — the heart deserves dedicated iron imaging promptly, because catching cardiac iron before symptoms become severe is what saves the heart.

Back to Table of Contents

Why Iron Builds Up in the First Place

The body has no efficient way to excrete iron — no built-in drain. It can only control how much it absorbs. So iron overload develops whenever iron comes in faster than the tiny amounts lost through shed skin and gut cells can keep pace with. The major routes are:

• Repeated blood transfusions (transfusional iron overload). Each unit of red cells delivers roughly 200–250 mg of iron that the body cannot get rid of. In someone transfused regularly for years, the load mounts relentlessly — this is the dominant cause of iron-overload heart disease globally, particularly in thalassemia major.
• Hereditary hemochromatosis. Genetic variants (most often in the HFE gene) dial down the body's iron-control hormone, so the gut absorbs more iron from ordinary food, decade after decade. It is one of the most common inherited conditions in people of Northern European ancestry. Full detail on hemochromatosis.
• Other inherited iron-loading disorders and chronic anemias in which the body mistakenly ramps up iron absorption (so-called ineffective red-cell production).
• Excessive iron from supplements or medical iron infusions given without a genuine deficiency — a smaller contributor for most people, but a real one over long periods, and especially risky in someone with an undiagnosed genetic predisposition. (See the broader picture on the iron overload hub.)

Two practical notes. First, dietary iron alone almost never causes overload in a person with normal genetics and no transfusions — you cannot eat your way into iron-overload cardiomyopathy from a normal diet. Second, the cause matters enormously for treatment: transfusional overload is managed with iron-binding drugs, whereas hereditary hemochromatosis is treated mainly by removing blood, as the next sections explain.

Back to Table of Contents

Getting Checked: Blood Tests and Cardiac Magnetic Resonance Imaging

Diagnosing iron-overload heart disease happens in two layers: first confirm that the body is iron-loaded, then measure how much iron is actually in the heart and what it is doing to function.

Step one — prove the iron overload (blood tests). Two markers do most of the work, and they are part of an Iron Panel:

• Transferrin saturation — the percentage of the blood's iron-carrying capacity that is filled. A persistently high value (commonly above about 45–50%) signals that transferrin is saturated and dangerous free iron may be circulating. This is often the earliest abnormal marker.
• Ferritin — a measure of total body iron stores. A high ferritin supports overload, though it is imperfect because ferritin also rises with inflammation, infection, and liver injury, so it is interpreted alongside the transferrin saturation rather than alone.

A broader Comprehensive Metabolic Panel checks the liver and kidneys for collateral damage and helps screen for the diabetes that often travels with iron overload. If hereditary hemochromatosis is suspected, genetic testing (for HFE variants) confirms it.

Step two — measure iron in the heart (cardiac magnetic resonance imaging). Here is the single most important advance in this field. Blood ferritin does not reliably tell you how much iron is in the heart — the heart can be loading even when other markers look only modestly raised. The breakthrough was a special magnetic resonance imaging technique called cardiovascular T2* (“T2-star”) magnetic resonance imaging, which non-invasively quantifies iron in the heart muscle itself. Iron distorts the magnetic resonance imaging signal in a measurable way: the more iron, the shorter the T2* value. A short cardiac T2* (below about 20 milliseconds) flags significant cardiac iron, and a very short value (below 10 ms) marks high risk. In a UK study of 652 people with thalassaemia major (Kirk and colleagues, 2009), a cardiac T2* below 20 ms carried 4.6 times the risk of an abnormal heart rhythm (arrhythmia), and a value below 10 ms carried 160 times the risk of heart failure, compared with values above those lines. The same scan measures the heart's pumping function and can also gauge liver iron.

This is genuinely good news for patients: T2* magnetic resonance imaging lets doctors detect cardiac iron before the heart fails, monitor it over time, and prove that treatment is working — turning a once-hidden, often-fatal process into something that can be watched and managed like a number on a chart. A standard echocardiogram (ultrasound) and an electrocardiogram (ECG) round out the picture by showing how the heart is contracting and whether the rhythm is disturbed, but it is the T2* magnetic resonance imaging that pinpoints the iron.

The same 652-patient study showed how strong the warning is. Heart failure developed within one year in 47% of patients whose cardiac T2* was below 6 ms, and in 98% of the scans of patients who went on to develop heart failure the cardiac T2* was below 10 ms. As a predictor of heart failure, cardiac T2* scored far better than blood ferritin (area under the curve 0.948 for cardiac T2* vs 0.629 for ferritin, where 1.0 would be a perfect predictor and 0.5 no better than chance).

Back to Table of Contents

How It Is Treated — and Why It Can Reverse

The central principle is hopeful and worth stating plainly: remove the excess iron and the heart can recover. Iron-overload cardiomyopathy is one of the few forms of heart muscle disease that is genuinely reversible when caught in time, because clearing iron from the cells lets the surviving heart muscle heal. Treatment runs on two tracks — getting the iron out, and supporting the heart while that happens.

Getting the iron out. The method depends on the cause:

• Iron chelation therapy is used when removing blood is not an option — chiefly in transfusional overload, where the patient is anemic and cannot spare blood. Chelators are drugs that grab onto iron so the body can excrete it. The three in wide use are deferoxamine (given by slow infusion), deferiprone, and deferasirox (both taken by mouth). Clinical trials using cardiac magnetic resonance imaging proved that chelation — especially combinations, and the oral agents over time — can measurably pull iron back out of the heart, improve T2* values, and recover pumping function. In thalassemia, the widespread use of effective chelation has dramatically reduced deaths from cardiac iron.
• Therapeutic phlebotomy — removing blood, like a controlled blood donation — is the mainstay for hereditary hemochromatosis. Because each unit of blood removed takes its iron with it, regular phlebotomy steadily draws down the body's stores until they normalize, then maintains them. It is simple, inexpensive, and effective, and when started before organ damage it can give a normal life expectancy.

Bringing less iron in. A newer approach works on the transfusions themselves. Luspatercept is an injected protein drug that helps red blood cells mature, so fewer transfusions may be needed. In the BELIEVE trial (336 adults with transfusion-dependent beta thalassaemia, 2020), 21.4% of people on luspatercept vs 4.5% on placebo met the main goal (at least a one-third cut in transfusions, and at least 2 fewer units, during weeks 13 to 24). Over any 12-week stretch of the trial, transfusions fell by at least a third in 70.5% of people on luspatercept vs 29.5% on placebo, and blood ferritin at week 48 was 348 µg per litre lower than with placebo. Short-lived bone pain, joint pain, dizziness, high blood pressure and raised uric acid were more common on the drug.

Supporting the heart. Alongside iron removal, the heart itself is managed with standard, evidence-based heart-failure care — medications that ease the heart's workload and clear fluid — and any arrhythmia is treated on its own merits, sometimes with rhythm-control drugs or a device. In advanced, unrecovered cases, the full range of advanced heart-failure therapies may be considered. But the disease-specific lever, the one that addresses the actual cause, is always the same: lower the iron.

What changes the course of the disease. In iron overload, the iron-removal schedule is what lowers the iron, and the periodic monitoring (ferritin, transferrin saturation, and cardiac magnetic resonance imaging) is how rising heart iron is caught early. Iron supplements add to the load, and high-dose vitamin C supplements increase iron absorption and can mobilize stored iron. Alcohol adds to the liver injury that iron causes. These are not vague wellness points — in this disease they directly change the trajectory of the heart.

Back to Table of Contents

Heart Checks and Emergency Warning Signs

Two situations deserve attention. The first is non-urgent but important: if you have a reason to be iron-loaded — regular transfusions, hereditary hemochromatosis, a long history of high-dose iron, or blood tests already showing a high ferritin and transferrin saturation — the heart can be loading iron before any symptom appears, and a cardiac T2* magnetic resonance imaging scan is the test that shows it. In the 652-patient UK study, a cardiac T2* below 10 ms carried 160 times the risk of heart failure, and the scan predicted heart failure far better than blood ferritin or liver iron. Catching cardiac iron early is the whole game.

The second is urgent. Hospitals treat each of the following as an emergency sign, whether or not iron is the known cause:

• Chest pain or pressure, especially with sweating, nausea, or pain spreading to the arm, neck, or jaw.
• Severe or sudden shortness of breath, breathlessness at rest, or waking gasping for air and unable to lie flat.
• Fainting, or near-fainting with palpitations — a blackout or near-blackout combined with a racing or chaotic heartbeat can signal a dangerous arrhythmia.
• A sustained, very fast, or wildly irregular heartbeat that does not settle, particularly with dizziness, chest discomfort, or breathlessness (see heart palpitations).
• Rapidly worsening leg, ankle, or abdominal swelling with breathlessness — a sign the heart is failing to keep up.

For a person known to be iron-loaded, the combination of new breathlessness, swelling, or palpitations is a reason for a prompt — not eventual — cardiac evaluation, because in this disease the window in which the heart can still fully recover is time-limited. Confirming or excluding cardiac iron is straightforward, and early iron removal is what preserves the heart.

Back to Table of Contents

Key Research Papers

1. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. (2003). L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nature Medicine;9(9):1187-1194. — DOI: 10.1038/nm920. — doi:10.1038/nm920
2. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH (1999). Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circulation Research;84(11):1302-1309. — DOI: 10.1161/01.RES.84.11.1302. — doi:10.1161/01.RES.84.11.1302
3. Murphy CJ, Oudit GY (2010). Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. Journal of Cardiac Failure;16(11):888-900. — DOI: 10.1016/j.cardfail.2010.05.009. — doi:10.1016/j.cardfail.2010.05.009
4. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. (2001). Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal;22(23):2171-2179. — DOI: 10.1053/euhj.2001.2822. — doi:10.1053/euhj.2001.2822
5. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. (2009). Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation;120(20):1961-1968. — DOI: 10.1161/CIRCULATIONAHA.109.874487. — doi:10.1161/CIRCULATIONAHA.109.874487
6. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. (2007). A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation;115(14):1876-1884. — DOI: 10.1161/CIRCULATIONAHA.106.648790. — doi:10.1161/CIRCULATIONAHA.106.648790
7. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. (2011). Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica;96(1):48-54. — DOI: 10.3324/haematol.2010.031468. — doi:10.3324/haematol.2010.031468
8. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A (2010). β-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circulation: Heart Failure;3(3):451-458. — DOI: 10.1161/circheartfailure.109.913863. — doi:10.1161/circheartfailure.109.913863
9. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y (2010). Iron overload cardiomyopathy: better understanding of an increasing disorder. Journal of the American College of Cardiology;56(13):1001-1012. — DOI: 10.1016/j.jacc.2010.03.083. — doi:10.1016/j.jacc.2010.03.083
10. Pietrangelo A (2004). Hereditary hemochromatosis — a new look at an old disease. New England Journal of Medicine;350(23):2383-2397. — DOI: 10.1056/NEJMra031573. — doi:10.1056/NEJMra031573
11. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O (2018). Haemochromatosis. Nature Reviews Disease Primers;4:18016. — DOI: 10.1038/nrdp.2018.16. — doi:10.1038/nrdp.2018.16
12. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010). Two to tango: regulation of mammalian iron metabolism. Cell;142(1):24-38. — DOI: 10.1016/j.cell.2010.06.028. — doi:10.1016/j.cell.2010.06.028
13. Padhani ZA, Gangwani MK, Sadaf A, Hasan B, Colan S, Alvi N, Das JK (2023). Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database of Systematic Reviews;11(11):CD011626. — DOI: 10.1002/14651858.CD011626.pub3. — PubMed PMID: 37975597
14. Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, et al.; BELIEVE Investigators (2020). A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. New England Journal of Medicine;382(13):1219-1231. — DOI: 10.1056/NEJMoa1910182. — PubMed PMID: 32212518

PubMed Topic Searches

1. PubMed: Iron-overload cardiomyopathy
2. PubMed: Cardiac T2* MRI and myocardial iron
3. PubMed: Iron chelation and cardiac iron in thalassemia
4. PubMed: Hemochromatosis, cardiac involvement, and arrhythmia
5. PubMed: Non-transferrin-bound iron and calcium-channel entry

Back to Table of Contents

Connections

• All Minerals
• Iron Overload Symptom Hub
• Iron Overload and Fatigue & Joint Pain
• Iron Overload and Liver Problems
• Iron Overload, Bronze Skin & Diabetes
• Iron Deficiency Symptom Hub
• Iron Overview
• Hemochromatosis
• Thalassemia
• Cardiomyopathy
• Heart Failure
• Arrhythmia
• Atrial Fibrillation
• Heart Palpitations
• Iron Panel
• Comprehensive Metabolic Panel

Back to Table of Contents

×

Featured Videos